Table 2.
Number of participants | All individuals | Individuals with a diagnosed cancer (all-site): | -Valuea | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No | Yes | |||||||||||||
19,348 | 15,637 | 3,711 | ||||||||||||
Annual mean | Median | 25th percentile | 75th percentile | IQR | Median | 25th percentile | 75th percentile | IQR | Median | 25th percentile | 75th percentile | IQR | ||
Baseline | Black carbon () | 2.65 | 2.23 | 3.33 | 1.10 | 2.65 | 2.23 | 3.34 | 1.11 | 2.63 | 2.22 | 3.27 | 1.05 | 0.351 |
() | 33.3 | 30.1 | 37.8 | 7.7 | 33.3 | 30.1 | 37.8 | 7.7 | 33.2 | 29.9 | 37.7 | 7.8 | 0.075 | |
() | 39.3 | 28.4 | 52.4 | 24.0 | 39.5 | 28.4 | 52.6 | 24.2 | 38.9 | 28.2 | 51.8 | 23.6 | 0.073 | |
Black carbon residuals | ||||||||||||||
Regressed on | 0.00 | 0.13 | 0.26 | 0.00 | 0.13 | 0.26 | 0.13 | 0.26 | 0.858 | |||||
Regressed on | 0.15 | 0.15 | 0.15 | 0.037 | ||||||||||
At censoring | Black carbon () | 1.82 | 1.52 | 2.34 | 0.82 | 1.77 | 1.49 | 2.26 | 0.77 | 2.04 | 1.67 | 2.61 | 0.94 | |
() | 21.1 | 18.9 | 24.7 | 5.7 | 20.8 | 18.7 | 23.8 | 5.1 | 23.9 | 20.1 | 28.8 | 8.7 | ||
() | 26.0 | 18.3 | 36.2 | 17.9 | 25.3 | 17.9 | 35.0 | 17.1 | 29.5 | 20.2 | 41.5 | 21.3 | ||
Black carbon residuals | ||||||||||||||
Regressed on | 0.09 | 0.26 | 0.09 | 0.27 | 0.14 | 0.29 | ||||||||
Regressed on | 0.07 | 0.17 | 0.20 | 0.08 | 0.17 | 0.18 | 0.02 | 0.13 | 0.22 |
Note: All-site cancer cases were defined as the whole ICD-10 chapter except C77–79 (secondary malignant neoplasms) and C44 (nonmelanoma skin cancers). Participants were excluded from the analysis if they were diagnosed with cancer before 1999. Exposures were lagged 10 y. IQR: Interquartile range.
-Value of Wilcoxon tests for differences between participants diagnosed with all-site cancer or not.